share_log

Should You Investigate Progyny, Inc. (NASDAQ:PGNY) At US$22.90?

Should You Investigate Progyny, Inc. (NASDAQ:PGNY) At US$22.90?

您是否應該以22.90美元的價格調查Progyny, Inc.(納斯達克:PGNY)?
Simply Wall St ·  09/12 20:22

Progyny, Inc. (NASDAQ:PGNY), might not be a large cap stock, but it saw a decent share price growth of 12% on the NASDAQGS over the last few months. Shareholders may appreciate the recent price jump, but the company still has a way to go before reaching its yearly highs again. With many analysts covering the mid-cap stock, we may expect any price-sensitive announcements have already been factored into the stock's share price. However, could the stock still be trading at a relatively cheap price? Let's take a look at Progyny's outlook and value based on the most recent financial data to see if the opportunity still exists.

Progyny, Inc.(納斯達克股票代碼:PGNY)可能不是大盤股,但在過去幾個月中,納斯達克證券交易所的股價上漲了12%。股東們可能會對最近的價格上漲表示讚賞,但該公司在再次達到年度高點之前還有很長的路要走。由於許多分析師都在報道中盤股,我們可能預計,任何對價格敏感的公告都已計入該股的股價。但是,該股票還能以相對便宜的價格交易嗎?讓我們根據最新的財務數據來看看Progyny的前景和價值,看看機會是否仍然存在。

Is Progyny Still Cheap?

Progyny 還便宜嗎?

Progyny is currently expensive based on our price multiple model, where we look at the company's price-to-earnings ratio in comparison to the industry average. In this instance, we've used the price-to-earnings (PE) ratio given that there is not enough information to reliably forecast the stock's cash flows. We find that Progyny's ratio of 32.94x is above its peer average of 26.97x, which suggests the stock is trading at a higher price compared to the Healthcare industry. But, is there another opportunity to buy low in the future? Since Progyny's share price is quite volatile, this could mean it can sink lower (or rise even further) in the future, giving us another chance to invest. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market.

根據我們的價格倍數模型,Progyny目前價格昂貴,在該模型中,我們將公司的市盈率與行業平均水平的比較來看。在這種情況下,鑑於沒有足夠的信息來可靠地預測股票的現金流,我們使用了市盈率(PE)。我們發現,Progyny的32.94倍比率高於同行平均水平的26.97倍,這表明與醫療保健行業相比,該股的交易價格更高。但是,未來還有其他低價買入的機會嗎?由於Progyny的股價波動很大,這可能意味着它將來可能會下跌(或進一步上漲),從而爲我們提供另一次投資機會。這是基於其較高的貝塔值,這是一個很好的指標,可以很好地衡量股票相對於其他市場的波動幅度。

What kind of growth will Progyny generate?

Progyny 會帶來什麼樣的增長?

big
NasdaqGS:PGNY Earnings and Revenue Growth September 12th 2024
納斯達克股票代碼:PGNY 收益和收入增長 2024 年 9 月 12 日

Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let's also take a look at the company's future expectations. Progyny's earnings over the next few years are expected to double, indicating a very optimistic future ahead. This should lead to stronger cash flows, feeding into a higher share value.

當你考慮買入股票時,未來前景是一個重要的方面,特別是如果你是尋求投資組合增長的投資者。以低廉的價格收購一家前景看好的優秀公司永遠是一項不錯的投資,因此,讓我們也來看看公司的未來預期。Progyny未來幾年的收益預計將翻一番,這表明未來非常樂觀。這應該會導致更強勁的現金流,從而提高股票價值。

What This Means For You

這對你意味着什麼

Are you a shareholder? PGNY's optimistic future growth appears to have been factored into the current share price, with shares trading above industry price multiples. However, this brings up another question – is now the right time to sell? If you believe PGNY should trade below its current price, selling high and buying it back up again when its price falls towards the industry PE ratio can be profitable. But before you make this decision, take a look at whether its fundamentals have changed.

你是股東嗎?PGNY樂觀的未來增長似乎已被納入當前股價的因素,股票的交易價格高於行業價格倍數。但是,這又帶來了另一個問題——現在是合適的賣出時機嗎?如果您認爲PGNY的交易價格應低於其當前價格,那麼高價賣出並在其價格跌至行業市盈率時再次回購可能會有利可圖。但是在做出這個決定之前,先看看它的基本面是否發生了變化。

Are you a potential investor? If you've been keeping an eye on PGNY for a while, now may not be the best time to enter into the stock. The price has surpassed its industry peers, which means it is likely that there is no more upside from mispricing. However, the positive outlook is encouraging for PGNY, which means it's worth diving deeper into other factors in order to take advantage of the next price drop.

你是潛在的投資者嗎?如果你關注PGNY已有一段時間了,那麼現在可能不是入股的最佳時機。該價格已經超過了業內同行,這意味着錯誤定價可能沒有更多的上行空間。但是,對於PGNY來說,樂觀的前景令人鼓舞,這意味着值得深入研究其他因素,以利用下一次價格下跌的機會。

Since timing is quite important when it comes to individual stock picking, it's worth taking a look at what those latest analysts forecasts are. Luckily, you can check out what analysts are forecasting by clicking here.

由於在挑選個股時,時機非常重要,因此值得一看分析師的最新預測是什麼。幸運的是,您可以點擊此處查看分析師的預測。

If you are no longer interested in Progyny, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

如果您不再對Progyny感興趣,可以使用我們的免費平台查看我們列出的其他50多隻具有高增長潛力的股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接聯繫我們。或者,也可以發送電子郵件至編輯團隊 (at) simplywallst.com。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論